Sanofi's Commitment to Diabetes

Author: By Sanofi

Editorial Team

Supporting you with reliable and sustainable insulin supply

A Century of Insulin Experience

Development

Production

Supply Chain

Therapy

For over 100 years, Sanofi has been committed to the development and production of insulin therapies for people living with diabetes¹. Our long-standing heritage in diabetes care has enabled us to build extensive expertise in insulin manufacturing and supply chain management.

Our Commitment to Supply Sustainability

Sanofi recognises the critical importance of maintaining a reliable insulin supply for patients who depend on our treatments. We maintain robust contingency plans and strategic inventory management to help ensure continuity of supply across our insulin portfolio.

Investment in Manufacturing Capabilities

We continue to invest in our global manufacturing network to enhance production capacity and implement technological advancements. Our manufacturing facilities operate to rigorous quality standards, with regular monitoring and evaluation to maintain compliance with international regulatory requirements.

Evaluating the Environmental Impact Across the Pen Manufacturing Chain

Toujeo®(insulin glargine U300) pens have been developed with a strong focus on environmental sustainability, supported by a rigorous ISO-certiﬁed Life Cycle Assessment (LCA) conducted in 2024.¹This assessment evaluated the environmental footprint of the product across its entire lifecycle—from raw material sourcing to manufacturing, distribution, use, and disposal. The eco-design approach has led to the below environmental gains, by optimising each step of Toujeo's product lifecycle:¹

Low Carbon Footprint

Less Water Usage

Reduce in overall resource use

A key milestone in this journey is the transition to 100% renewable electricity across all insulin manufacturing facilities, reinforcing our commitment to sustainable healthcare delivery.¹

^{1. Toujeo® Environmental Claims. MAT-GLB-2502484. Based on an ISO-compliant Life Cycle Assessment (LCA) conducted in 2024 on Sanoﬁ's insulin portfolio. July 2025.}

RePen Recycling Scheme

Sanofi is committed to reducing the environmental impact of diabetes care. The RePen recycling scheme allows patients to return used insulin pens for responsible disposal and recycling.

For more information about the RePen recycling programme and to find your nearest participating location, please visit mysanofiinsulin.co.uk/repen